SG11202113226QA - Antiarrhythmic formulation - Google Patents
Antiarrhythmic formulationInfo
- Publication number
- SG11202113226QA SG11202113226QA SG11202113226QA SG11202113226QA SG11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA
- Authority
- SG
- Singapore
- Prior art keywords
- antiarrhythmic
- formulation
- antiarrhythmic formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881689P | 2019-08-01 | 2019-08-01 | |
| US16/901,941 US11020384B2 (en) | 2019-08-01 | 2020-06-15 | Antiarrhythmic formulation |
| US16/901,909 US11007185B2 (en) | 2019-08-01 | 2020-06-15 | Antiarrhythmic formulation |
| PCT/US2020/044291 WO2021022058A2 (en) | 2019-08-01 | 2020-07-30 | Antiarrhythmic formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202113226QA true SG11202113226QA (en) | 2021-12-30 |
Family
ID=74229279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202113226QA SG11202113226QA (en) | 2019-08-01 | 2020-07-30 | Antiarrhythmic formulation |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4007576A4 (en) |
| JP (3) | JP7190077B2 (en) |
| KR (1) | KR102491733B1 (en) |
| CN (1) | CN114144177A (en) |
| AU (3) | AU2020323594B2 (en) |
| CA (1) | CA3139748A1 (en) |
| IL (3) | IL290088B2 (en) |
| SG (1) | SG11202113226QA (en) |
| WO (1) | WO2021022058A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| WO2022133317A1 (en) | 2020-12-17 | 2022-06-23 | Incarda Therapeutics, Inc. | Kits and methods for induction of cardioversion in subjects with atrial arrhythmias |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ276305A (en) * | 1993-11-16 | 1997-10-24 | Depotech Corp | Controlled release vesicle compositions |
| US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| EP1809240A4 (en) * | 2004-10-12 | 2010-06-16 | Alexza Pharmaceuticals Inc | Cardiac safe, rapid medication delivery |
| US20070178050A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an increased lung depositon |
| CN101472589A (en) * | 2006-04-06 | 2009-07-01 | 先灵公司 | Use of a composition comprising a thrombin receptor antagonist for the preparation of a medicament for the treatment of cardiovascular diseases |
| EP2413902B1 (en) * | 2009-03-18 | 2019-07-17 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| WO2017136421A1 (en) * | 2016-02-01 | 2017-08-10 | Incarda Therapeutics, Inc. | Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation |
| JP2020519628A (en) * | 2017-05-10 | 2020-07-02 | インカーダ セラピューティクス, インコーポレイテッド | Unit doses, aerosols, kits and methods for treating cardiac conditions by pulmonary administration |
| EP3621591A1 (en) * | 2017-05-11 | 2020-03-18 | Steadymed Ltd. | Enhanced solubility drug-containing formulations |
| GB2564444B (en) * | 2017-07-10 | 2020-09-16 | Syri Ltd | Liquid pharmaceutical composition of flecainide |
-
2020
- 2020-07-30 SG SG11202113226QA patent/SG11202113226QA/en unknown
- 2020-07-30 CA CA3139748A patent/CA3139748A1/en active Pending
- 2020-07-30 CN CN202080052432.0A patent/CN114144177A/en active Pending
- 2020-07-30 JP JP2022506507A patent/JP7190077B2/en active Active
- 2020-07-30 EP EP20848179.6A patent/EP4007576A4/en active Pending
- 2020-07-30 AU AU2020323594A patent/AU2020323594B2/en active Active
- 2020-07-30 IL IL290088A patent/IL290088B2/en unknown
- 2020-07-30 WO PCT/US2020/044291 patent/WO2021022058A2/en not_active Ceased
- 2020-07-30 KR KR1020227003421A patent/KR102491733B1/en active Active
- 2020-07-30 IL IL321589A patent/IL321589A/en unknown
-
2022
- 2022-04-29 AU AU2022202842A patent/AU2022202842B2/en active Active
- 2022-12-02 JP JP2022193405A patent/JP7611211B2/en active Active
-
2023
- 2023-05-21 IL IL303094A patent/IL303094B2/en unknown
-
2024
- 2024-02-29 AU AU2024201359A patent/AU2024201359A1/en active Pending
- 2024-10-10 JP JP2024178404A patent/JP2025004215A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL290088B2 (en) | 2023-10-01 |
| IL303094A (en) | 2023-07-01 |
| IL303094B1 (en) | 2025-07-01 |
| JP7611211B2 (en) | 2025-01-09 |
| AU2020323594B2 (en) | 2022-02-03 |
| CA3139748A1 (en) | 2021-02-04 |
| IL321589A (en) | 2025-08-01 |
| IL290088B1 (en) | 2023-06-01 |
| JP2025004215A (en) | 2025-01-14 |
| WO2021022058A3 (en) | 2021-04-08 |
| JP2022533477A (en) | 2022-07-22 |
| KR102491733B1 (en) | 2023-01-27 |
| KR20230014882A (en) | 2023-01-30 |
| AU2020323594A1 (en) | 2021-12-23 |
| JP2023022251A (en) | 2023-02-14 |
| JP7190077B2 (en) | 2022-12-14 |
| AU2022202842A1 (en) | 2022-05-19 |
| IL303094B2 (en) | 2025-11-01 |
| EP4007576A2 (en) | 2022-06-08 |
| IL290088A (en) | 2022-03-01 |
| AU2022202842B2 (en) | 2024-02-22 |
| CN114144177A (en) | 2022-03-04 |
| EP4007576A4 (en) | 2023-05-10 |
| AU2024201359A1 (en) | 2024-03-21 |
| KR20220025071A (en) | 2022-03-03 |
| WO2021022058A2 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282617A (en) | Aerosolisable formulation | |
| IL290447A (en) | Pharmaeutical composition comprising ensifentrine | |
| IL276011A (en) | Group b adenovirus-containing formulation | |
| IL282567A (en) | Aerosolisable formulation | |
| IL282523A (en) | Aerosolisable formulation | |
| IL282589A (en) | Aerosolisable formulation | |
| GB201816447D0 (en) | Formulation | |
| IL282461A (en) | Aerosolisable formulation | |
| IL282697A (en) | Aerosolisable formulation | |
| GB201817863D0 (en) | Aerosolisable formulation | |
| IL290088A (en) | Antiarrhythmic formulation | |
| IL284688A (en) | Formulation | |
| GB201913232D0 (en) | Aerosolisable formulation | |
| GB201813229D0 (en) | Formulation | |
| GB201811926D0 (en) | Aerosolisable formulation | |
| GB201807312D0 (en) | Formulation | |
| HK40067172A (en) | Antiarrhythmic formulation | |
| HK40075133A (en) | Antiarrhythmic formulation | |
| GB2587402B (en) | Formulation | |
| GB2599912B (en) | New formulation | |
| GB202115303D0 (en) | New formulation | |
| GB202108181D0 (en) | New formulation | |
| GB201906242D0 (en) | Aerosolisable formulation | |
| GB201900658D0 (en) | Formulation | |
| GB202003048D0 (en) | Formulation |